ClinicalTrials.gg

Program

uliledlimab

Also written as “TJ004309” and “Uliledlimab”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Neoplasm Metastasis, led by 3 companies.

Furthest: phase 3, since Apr 22, 20254 company-led studies, 1 open or runningNext primary completion: Aug 5, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TJ Biopharma21 open or runningphase 3since Apr 22, 2025Mar 17, 2020Aug 5, 2028phase 3 · NCT06984588
I-Mab Biopharma US10 open or runningphase 2since Jul 12, 2021Jul 12, 2021none ahead
Tracon Pharmaceuticals10 open or runningphase 1since Feb 5, 2019Feb 5, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 5, 2019First study: phase 1 study in Neoplasm MetastasisNew to Tracon PharmaceuticalsTracon Pharmaceuticals · NCT03835949 · 36 enrolled · United States
  2. Mar 17, 2020TJ Biopharma's first study: phase 2 study in Advanced Solid TumorNew to TJ BiopharmaTJ Biopharma · NCT04322006 · 225 enrolled · China
  3. Jul 12, 2021I-Mab Biopharma US's first study: phase 2 study in Ovarian NeoplasmsNew to I-Mab Biopharma USI-Mab Biopharma US · NCT05001347 · 25 enrolled · United States
  4. Apr 22, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungTJ Biopharma · NCT06984588 · 450 enrolled · China

Ahead

  1. Aug 5, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungTJ Biopharma · NCT06984588

TargetBeta

NT5E →read by rule
“A humanized monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), ”NCIt, by rule

Other programs on NT5E

ProgramCompanyFurthest phaseStudies
oleclumabAstraZenecaphase 38
quemliclustatruleArcus Biosciencesphase 37

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06984588Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingTJ BiopharmaAug 5, 2028450
NCT05001347Ovarian Neoplasms · United States2CompletedI-Mab Biopharma USFeb 8, 202325
NCT04322006Advanced Solid Tumor · China2CompletedTJ BiopharmaApr 30, 2025225
NCT03835949Neoplasm Metastasis · United States1UNKNOWNTracon PharmaceuticalsJun 202236

How it is read

Names in the registry

  • “TJ004309”, 3 entries
  • “Uliledlimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.